Phio Pharmaceuticals’ lead clinical program is PH-762 (often referred to in the context of their INTASYL platform), which is an investigational, self-delivering RNAi compound designed to treat skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results